Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph þ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicenter trial, we compared the tolerability and efficacy of post-transplant imatinib administered either prophylactically (arm A; n ¼ 26) or following detection of MRD (arm B; n ¼ 29). Prophylactic imatinib significantly reduced the incidence of molecular recurrence after SCT compared with MRD-triggered imatinib (40% vs 69%; P ¼ 0.046). Median duration of PCR negativity was 26.5 and 6.8 months, respectively (P ¼ 0.065). Five-year survival in both interventional groups was high (80 and 74.5%), despite premature discontinuation of imatinib in the majority of patients because of poor tolerability. Relapse probability was significantly higher in patients who became MRD positive (P ¼ 0.017). In conclusion, posttransplant imatinib results in a low relapse rate, durable remissions and excellent long-term outcome in patients with BCR-ABL1-positive ALL irrespective of whether it is given prophylactically or MRD-triggered. Reappearance of BCR-ABL1 transcripts early after SCT or at higher levels identifies a small subset of patients who do not benefit sufficiently from imatinib, and in whom alternative approaches should be explored.
INTRODUCTION
The prognosis of patients with Ph þ acute lymphoblastic leukemia (ALL) has improved considerably with use of BCR-ABL1-directed tyrosine kinase inhibitors (TKIs) in front-line treatment. Complete remission (CR) rates routinely exceed 90%, and outcome is superior compared with historic controls, but the probability of relapse remains high. [1] [2] [3] [4] [5] [6] [7] [8] Allogeneic stem cell transplantation (SCT) performed in first CR (CR1) is currently considered to be the best potentially curative treatment option, [9] [10] [11] with long-term diseasefree survival (DFS) ranging from 30 to 47%. (1, 12, 13) In several studies not utilizing imatinib after allogeneic SCT in CR1, overall survival (OS) at 3 years was 64% and 57%, respectively, and the MRC reported 5-year OS of 44% after sibling SCT and 36% after matched unrelated donor SCT. Relapse remains a major cause of treatment failure even after SCT. 3, 5, [12] [13] [14] [15] [16] [17] Despite salvage therapy with imatinib 18 or second-generation TKI, 19, 20 the prognosis is extremely poor. Accordingly, prevention of hematologic relapse is essential for improving the results of SCT in adult Ph þ ALL. Appearance of BCR-ABL1 transcripts after SCT is associated with a high risk of relapse 21 and identifies patients who may benefit from therapeutic intervention. Discontinuation of immunosuppressive therapy and donor lymphocyte infusions have shown little efficacy in ALL. 22, 23 Administration of ABLdirected TKI to prevent relapse and re-establish molecular negativity in patients who remain or become PCR positive after SCT therefore is conceptually attractive. We hypothesized that molecular responses and overall treatment outcome could be improved by starting imatinib early after SCT, when the leukemic cell burden is likely to be low.
The clinical consequences of starting imatinib during the early post-transplant period have not yet been systematically studied. Available data are limited mostly to few case reports and small retrospectively analyzed series [24] [25] [26] with only two prospective studies published to date. 18, 27 The current randomized study was designed to compare two interventional strategies, in which imatinib was given either prophylactically as soon as clinically feasible, or minimal residual disease (MRD) triggered following the first detection of BCR-ABL1 transcripts.
PATIENTS AND METHODS Patients
Patients (X18 years) with Philadelphia chromosome-positive ALL or lymphoid blast crisis of chronic myeloid leukemia who received an allogeneic SCT while in CR were eligible. There were no restrictions regarding type of transplant, conditioning regimens or transplantation in first or subsequent CR. Criteria for starting imatinib included sufficient recovery of absolute neutrophil count (X Â 10 9 /l) and platelet (X50 Â 10 9 /l) counts, absence of uncontrolled graft-vs-host disease (GvHD) or infections, ECOG performance status 0-2 and adequate organ function. All patients gave prior written informed consent to participate in the study.
Methods for MRD assessment
Analysis of MRD was performed centrally in the studýs reference laboratory in Frankfurt using quantitative real-time PCR analysis and confirmatory testing by nested PCR as previously described. 28 Peripheral blood and bone marrow mononuclear cells were separated by Ficoll centrifugation. Total RNA was extracted with RNABee (Ambion, Invitrogen, Darmstadt, Germany), complementary DNA was synthesized from 1-5 mg RNA using MMLV, Promega, Mannheim, Germany and random hexamers, Applied Biosystems, Darmstadt, Germany and real-time PCR was performed with EAC primer and probe set. ABL was used as housekeeping gene. Low MRD level is defined as a BCR-ABL1/ABL1 ratio below or equal to 10 À 4 , an intermediate level as 410 À 4 and o10 À 2 , and a high level as 410 À 2 . For the low level or negative MRD, the ABL copy number had to be at least 10 4 .
Study design and treatment
This report is a planned interim analysis of the first 55 patients who were enrolled between January 2004 and September 2010, and were randomly assigned to receive imatinib (target dose 600, 400 mg permitted) either prophylactically (arm A; n ¼ 26) or MRD triggered (arm B; n ¼ 29).
The study remains open with additional accrual. Detection of BCR-ABL1 transcripts on a single occasion, if confirmed by nested PCR, was sufficient for study entry; confirmatory assessment was not mandatory to minimize delays in starting imatinib therapy. Imatinib administration was scheduled for 1 year of continuous PCR negativity. A schematic depiction of the study design is given in Supplementary Figure 1 . Patients randomized to the prophylactic treatment arm who already were PCR positive before having started imatinib treatment were kept in the prophylactic treatment arm and analyzed on an intention-to-treat basis. The study was reviewed and approved by the ethics committee of Frankfurt University. The study was performed in accordance with the Declaration of Helsinki.
Assessment of safety and efficacy
Clinical and laboratory evaluations were performed as previously described. 29, 30 Molecular recurrence after SCT was defined as the appearance of BCR-ABL1 transcripts by quantitative real-time PCR and/or nested PCR in patients who after SCT had been PCR negative by quantitative real-time PCR of sufficient sensitivity (ABL 410 4 ). Duration of PCR negativity from SCT was defined as the time from SCT to first appearance of BCR-ABL1 transcripts. An MRD-positive patient treated with imatinib was considered to be MRD-negative when no BCR-ABL1 transcripts were detected in two consecutive bone marrow and/or peripheral blood samples. Remission duration (RD) was defined as the time from SCT to reappearance of leukemic blasts in bone marrow and/or peripheral blood by conventional morphologic criteria or the occurrence of extramedullary disease. OS was measured from time of SCT until death, DFS from SCT until relapse or death, event-free survival (EFS) to relapse, death or change to an alternative therapy.
Statistical analysis
Primary end points were molecular recurrence and hematologic relapse. Secondary end points were non-relapse mortality, RD, OS and DFS, grade III or IV toxicities, and premature discontinuation of imatinib. For evaluation of efficacy and safety, differences between the two treatment groups were assessed by w 2 test without Yates correction, the Wilcoxon Mann-Whitney U-test or log-rank test, depending on the variable of interest. Duration of PCR negativity, RD, OS, DFS and EFS curves were plotted according to the methods of Kaplan-Meier, with differences between patient groups analyzed by the log-rank test. Patients who were switched to an alternative TKI were censored for RD and DFS at the time of imatinib discontinuation. Statistical analyses were performed using the GraphPad Prism (San Diego, CA, USA) software package.
RESULTS

Patients and treatment
Patient demographics and baseline characteristics are listed in Table 1 . Fifty-five patients with Ph-positive ALL (n ¼ 54) or chronic myeloid leukemia in lymphoid blastic phase (n ¼ 1) are included in this analysis. Twenty-six patients were randomly assigned to arm A (prophylactic imatinib), and 29 patients to arm B (MRD-triggered imatinib). The time interval between SCT and starting imatinib was 48 days (range: 23-88 days) in arm A and 70 days (range: 39-567 days) in arm B, the median interval from diagnosis to SCT in the two treatment arms was 4.5 and 4.8 months, respectively. Prior chemotherapy, use of imatinib during front-line therapy and transplant characteristics are summarized in Table 1 .
Molecular recurrence by treatment arm
The first MRD analysis conducted early, that is, within 3 months after SCT (median 34 days; range: 23-81 days) revealed that 11 of 51 (22%) evaluable patients were already PCR positive before imatinib was started ( Table 2) . At this early time point, the proportion of patients with detectable BCR-ABL1 transcripts was similar in arms A (22%) and B (21%). Similarly, the time from SCT to first detection of MRD in these 11 patients did not differ between treatment arms (median 31 and 28 days in arms A and B, respectively; Table 2 ).
Serial MRD analyses after SCT were performed in all but one patient ( Table 2) . BCR-ABL1 transcripts were detected at least once after SCT in 30 of 54 (56%) evaluable patients; their frequency was significantly lower in patients assigned to arm A (10/26; 40%) than arm B (20/29; 69%; P ¼ 0.046 by w 2 test; Table 2 ). By Kaplan-Meier analysis, the probability of remaining PCR negative was higher for patients allocated to prophylactic than to MRD-triggered imatinib, 45.6% vs 27.4% at 46 months, respectively ( Figure 1 ). The median duration of sustained PCR negativity in arms A and B was 26.5 and 6.8 months, respectively (P ¼ 0.065 by Wilcoxon Mann-Whitney U-test). In patients who became MRD positive, the median time to first detection of BCR-ABL1 transcripts was 4.1 months (0.9-26.5 months), with no significant difference between treatment arms (Table 2 ). In all, 24 of the 26 patients randomized to arm A actually received imatinib (Table 3) . BCR-ABL1 transcripts recurred in only two patients while imatinib was ongoing, five patients converted to PCR positivity before imatinib was started and two patients after it had been discontinued ( Table 2) . A slightly higher proportion of patients in the MRD triggered than the prophylactic imatinib arm had intermediate or high MRD levels before SCT (52% vs 37%; P ¼ NS; Table 4 ). However, the frequency of PCR positivity and time between SCT and first detection of MRD did not differ significantly between treatment groups. Surprisingly, there was no clear association between the BCR-ABL1 transcript level before SCT and PCR positivity early after SCT in either of the treatment arms (Table 4 ). An analysis of other potential prognostic variables revealed no statistically significant effect of age, sex, white blood cell at diagnosis, SCT in CR1 vs 4CR1, sibling vs matched unrelated donor SCT, myeloablative vs reduced intensity conditioning or minor vs major BCR-ABL1 breakpoint on RD and OS after SCT (data not shown).
Clinical outcome in relation to MRD status Reappearance of MRD at any time after SCT was associated with a significantly shorter RD (Figure 2a ). The probability of being relapse free at 5 years was 70.2% in patients who were PCR positive at least once after SCT and 100% in patients who remained PCR negative (P ¼ 0.017). Notably, the time to first appearance of BCR-ABL1 transcripts was prognostically relevant: patients with early molecular recurrence, based on a 100 day cutoff, had an only 50% probability of remaining relapse free at 4 years, despite intervention with imatinib ( Figure 2b ). EFS at 4 years was also significantly inferior in patients with early compared with delayed MRD positivity (38.6% vs 65%; median EFS 39 months vs not reached, respectively; Figure 2c ). The relationship between BCR-ABL1 transcript levels and outcome is depicted in Tables 5a  and 5b . Notably, the subgroup of patients with early molecular recurrence and/or BCR-ABL1 transcripts above 10 À 4 appears to derive limited benefit from intervention with imatinib. In all, 6 of 19 patients (31.6%) fulfilling these criteria eventually relapsed and 3 patients (15.8%) were switched to dasatinib after imatinib failed to induce sustained PCR negativity (Tables 5a and 5b ).
MRD-triggered imatinib: molecular and clinical response
In total, 13 of the 20 patients who were assigned to treatment arm B and became MRD positive received imatinib, starting a median of 18 days (9-47 days) after detection of BCR-ABL1 transcripts and 70 days (range: 39-726 days) after SCT. Conspicuously, the investigator's clinical decision to start imatinib or await the results of confirmatory MRD analysis differed according to the time to reappearance and the level of BCR-ABL1 transcripts (Table 5a) . A 100-day cutoff was found to best separate two patients groups characterized by either early recurrence of BCR-ABL1 transcripts (n ¼ 9) a median of 1.2 months (0.9-2.6 months) after SCT or delayed recurrence (n ¼ 11) a median of 6.7 months (3.5-24.2 months) after SCT.
Imatinib was started without awaiting confirmatory analysis in eight of nine patients with early recurrence, seven of whom had BCR-ABL1 transcripts levels below the quantitative range. Despite early intervention, only two of the eight (25%) imatinib-treated patients achieved sustained MRD negativity and remain in CR. The clinical course and outcome of the other six imatinib-treated patients are provided in Table 5a .
Long-term outcome was more favorable in patients with delayed MRD recurrence (n ¼ 11), 9 of whom had BCR-ABL1/ABL transcripts below the quantitative range. Overall, only 2 of 11 patients with 'late' MRD recurrence relapsed, 1 died in CR and 7 remain MRD negative at latest follow-up (Table 5a ).
Prophylactic imatinib: molecular and clinical response The molecular response and long-term clinical outcome of the MRD-positive patients are shown in Table 5b . Imatinib resulted in at least temporary PCR negativity in all 10 patients, including 3 patients who presented with intermediate or high MRD levels. In all, 3 of the 10 patients subsequently lost their molecular response and eventually relapsed despite imatinib. The relationship between MRD level or kinetics of PCR positivity and outcome is shown in Table 5b : six of seven patients with BCR-ABL1/ABL transcripts below the quantitative range attained PCR negativity that was durable. A single patient who took imatinib irregularly relapsed. Elucidation of risk factors other than MRD levels is precluded by the small number of patients with molecular recurrence in the prophylactic imatinib arm.
Outcome by treatment group With a median follow-up after SCT of 30.3 months (range: 5.3-64.2 months) and 32.4 months (range: 9.5-68.3 months) in arms A and B, respectively, 44 patients (82%) remain in CR, with no difference between treatment arms (81% vs 78%; Table 3 ). Relapses occurred in 5 of 50 patients transplanted in CR1 and in 2 of 5 patients transplanted in or beyond CR2. Three patients relapsed while receiving imatinib, 2, 5 and 10 months after SCT, respectively. The remaining four relapses occurred 1.5, 1.5, 12 and 19 months after imatinib had been discontinued and in one patient who never received imatinib. None of the four patients who died in CR had evidence of molecular relapse at the time of death. At 5 years after SCT, the probabilities of ongoing remission, DFS, OS and EFS were 82.6%, 69.4%, 77.3% and 62.5%, respectively, with no statistically significant difference between study arms (Figure 3 ).
Incidence and severity of GvHD and immunosuppression. As the presence of GvHD coincides with graft vs leukemia (GvL) activity, we assessed the incidence and severity of acute and chronic GvHD and its relation to MRD response and clinical outcome (Supplementary Table 1 ). The overall frequency of acute and chronic GvHD of all grades was 63% and 65%, respectively.
Comparison of both treatment arms revealed that the proportion of patients who did not develop acute GvHD was higher among patients who became MRD positive (13/27) than those who remained MRD negative (7/27) throughout the study (48% vs 26%). No significant difference was noted with regard to chronic GvHD (limited in 12/27 (44%) vs 8/27 (30%), extensive in 4/27 (15%) vs 11/27 (41%), none in 11/27 (41%) vs 8/27 (30%)). The median duration of immunosuppressive therapy (IS) was shorter in the MRD-positive patients (181 vs 281 days), because of more rapid tapering with the intention of inducing GvL. As the effect of imatinib on molecular and hematologic response may be confounded by IS and the speed of tapering, we evaluated IS given at the start of imatinib and its reduction during the early treatment phase (Supplementary Table 1 ). In all, 5 of the 27 MRD-positive patients received no IS, 15 full level IS and 7 had already started tapering. Of the eight patients who rapidly discontinued IS, three relapsed and one had an MRD increase, four converted to MRD negativity. Two of seven patients who required continuation of full IS relapsed. Taken together, no correlation could be established between MRD response and outcome and IS during the early study period (Supplementary Table 1 ). The use of antithymocyte globulin during conditioning had no impact on RD or DFS (data not shown).
Compliance and toxicity Following randomization, imatinib was started in 38 of 46 patients who became eligible to receive imatinib, with 26 patients starting at 400 mg and 12 patients at 600 mg. Imatinib was dose escalated in four patients, and dose reduced in nine patients (24%) for hematotoxicity (n ¼ 5), gastrointestinal toxicity (n ¼ 5) and combined hematologic and gastrointestinal toxicity (n ¼ 1). Imatinib was interrupted in 19 of 38 (50%) patients, for a median duration of 29 days (range: 2-140 days).
Imatinib was discontinued prematurely in the majority of patients, 16 (67%) in arm A and 10 (71%) in arm B; only 12 patients received imatinib for the scheduled duration (Table 3) . Severe adverse events leading to discontinuation of imatinib were gastrointestinal intolerance (n ¼ 6), GvHD (n ¼ 2), retinal hemorrhage with papillary edema (n ¼ 1), neutropenia (n ¼ 1), pulmonary fibrosis (n ¼ 1), graft failure (n ¼ 1), renal and hepatic function abnormalities (n ¼ 1), non-compliance (n ¼ 2), death in CR (n ¼ 1). . By KaplanMeier analysis, the probability of remaining PCR negative at 46 months after SCT is 45.6% with prophylactic and 27.4% with MRDtriggered imatinib (P ¼ 0.074 by log-rank test).
Four patients discontinued prematurely because of relapse and two patients because of persistence of MRD positivity. The median cumulative duration of imatinib exposure in treatment arms A and B was 201 days (range: 4-927 days) and 127 days (range: 18-964 days), respectively.
DISCUSSION
To reduce the relapse frequency and improve outcome of Ph þ ALL patients after allogeneic SCT, we compared the prophylactic use of imatinib with preemptive administration following detection of MRD. Our study design was based on the following considerations: (i) conversion to PCR positivity after SCT has been associated with evolving relapse, 21 making comparison with a purely observational approach unethical in the era of TKIs, (ii) treating all transplanted patients irrespective of MRD status entails overtreatment of a subset of patients destined to be cured by allogeneic SCT alone and (iii) imatinib can most likely re-establish molecular remission and prevent hematologic relapse in a greater proportion of patients than in our previous study when started earlier after SCT. 18 Therefore, the safety and efficacy of early post-SCT imatinib needed to be established.
Molecular recurrence was observed in 56% of patients overall but was significantly less frequent with prophylactic than with MRD-triggered imatinib. In most cases (73%), MRD preceded the start of imatinib or appeared after it had been discontinued; few patients converted to PCR positivity while actually receiving imatinib. By starting or reinitiating imatinib, durable PCR negativity was achieved in the majority of patients. Although prophylactic imatinib prevented molecular recurrence and was associated with a longer duration of PCR negativity than MRD-triggered intervention, RD, DFS, EFS and OS did not differ significantly between the two treatment arms. When data from both arms were combined, molecular response rate, RD (83% at 5 years) and survival (77% at 5 years) were substantially higher than in our previous study, 18 in which the interval between SCT and imatinib was 5 months, as opposed to a median of o2.5 months in this study. In contrast to a recently reported retrospective analysis, 31 our data thus provide compelling evidence that early posttransplant imatinib can effectively prevent molecular and as a consequence subsequent hematologic relapse, resulting in excellent RD (83% at 5 years) and survival (77% at 5 years). Our data are in agreement with a recently published single-arm study involving a mixed adult and pediatric Ph þ ALL population, which demonstrated a lower cumulative incidence of relapse in the imatinib-treated group and 5-year OS and DFS of 86.7% and 81.5%, respectively. 32 Superiority of post-transplant imatinib is also suggested by historical comparisons in three studies not utilizing imatinib after allogeneic SCT in CR1: the Japanese Acute leukemia Study Group and GMALL reported 3-year OS of 64% and 57%, respectively (LIT), and the MRC UKALLXII/ECOG2993 study showed 5-year OS of 44% after sibling SCT and 36% after matched unrelated donor SCT. 5, 6, 11 The short median time interval between SCT and appearance of BCR-ABL1 transcripts (4.1 months), in conjunction with our demonstration that recurrence of MRD early after SCT or at a BCR-ABL1/ ABL1 ratio 410 À 4 is associated with a significantly inferior outcome, highlights the need to monitor MRD frequently and at high sensitivity, starting early after SCT. As the molecular threshold for intervention in the MRD-triggered arm was very low, it is conceivable that some patients may not have required intervention. Based on the results of previous studies, 18, 21 we considered it essential to avoid treatment delays resulting in a higher leukemic cell burden less effectively controlled by TKI.
The prognostic relevance of MRD kinetics and levels shown in our study strongly supports prompt intervention with a TKI rather than time consuming confirmatory MRD analysis in patients with appearance of BCR-ABL1 transcripts early (o100 days) and/or at higher level (410 À 3 ) after SCT. Notably, this subgroup of patients appears to derive limited benefit from intervention with imatinib, as 47% of patients fulfilling these criteria eventually relapsed or were switched to dasatinib because of persisting MRD.
In contrast, confirmatory PCR analysis before starting a TKI appears justified in patients converting to PCR positivity at a level below the quantitative range and later than 100 days after SCT. Surprisingly, the BCR-ABL1 transcript level before SCT had no clear impact on the frequency and kinetics of MRD positivity after SCT in either of the treatment arms (Table 4) . Taken together, the predictive value of MRD emphasizes the need for standardized, highly sensitive PCR analysis in post-transplant management of Ph þ ALL.
Although we attempted to avoid a selection bias by randomizing patients only within 6 weeks after SCT, only patients with a good performance status and who survived at least 6 weeks after SCT were actually included. We have limited information on the number of patients who were not enrolled because of severe complications or death very early after SCT. Although this does not affect our conclusions regarding the predictive role of MRD and the impact of interventional imatinib, a selection bias may have contributed to the excellent long-term outcome.
Considering prior reports showing the feasibility of administering TKI after SCT for Ph þ ALL, 24, 25, [27] [28] [29] 31 the relatively poor tolerability of imatinib in the post-transplant setting was unanticipated. The imatinib dose was lower than intended because of frequent dosing interruptions and premature discontinuation in the majority of patients. As OS was remarkably high in both arms (80% and 74.5% after 5 years, P ¼ NS), an even relatively short exposure to TKI may control residual leukemia sufficiently for immunologic GvL activity to become effective. The majority of patients with molecular recurrence were on immunosuppressive therapy at the time of first PCR positivity and start of imatinib. It is therefore conceivable that tapering and discontinuation of immunosuppression during imatinib administration contributes to the MRD response by inducing a GvL effect. Of the patients who achieved PCR negativity, 54.5% were still receiving immunosuppression when they were found to be PCR negative. Overall, we were unable to demonstrate a correlation between immunosuppression or GvHD during the study period and either early MRD response or long-term outcome. Owing to the study design and the limited number of patients, we are unable to dissect the relative contributions of imatinib and GvL to eradication of the leukemic cells; based on an abundance of clinical data from the pre-imatinib era, however, imatinib clearly has a profound clinical impact.
Donor lymphocyte infusion may enhance the effect of TKI in advanced Ph þ leukemias. 33, 34 Their sporadic use in six patients in our study precludes assessment of their clinical value and safety, although our observation that four of these six patients relapsed does not suggest a profound benefit. Notably, only two of the four patients developed limited chronic GvHD. Nevertheless, administration of donor lymphocyte infusion in conjunction with a TKI appears warranted in patients who remain PCR positive with imatinib alone, although switching to a more potent TKI in conjunction with analysis of BCR-ABL1 mutation status should be strongly considered. Our study provides no evidence that imatinib impairs GvL in a clinically meaningful manner. Kaplan-Meier analysis of RD in patients with sustained PCR negativity after SCT and in patients with at least one positive PCR, irrespective of BCR-ABL1 transcript levels. The probability of ongoing remission 5 years after SCT is 100% and 70.2%, respectively (P ¼ 0.017 by log-rank test). (b) RD by the time period between SCT and conversion to PCR positivity based on a 100-day cutoff. RD was significantly shorter in patients in whom BCR-ABL1/ABL transcripts became detectable within 100 days after SCT (median 51.5 months vs not reached). (c) EFS in patients with early and late reappearance of MRD. Patients with molecular relapse within 100 days after SCT had a significantly shorter EFS (median 39 months vs not reached), the probability of being event free at 4 years was 38.6% vs 65% in patients with molecular recurrence later than 100 days after SCT (P ¼ 0.037 by log-rank test).
In conclusion, prophylactic imatinib significantly reduces the incidence of molecular relapse after SCT, and both prophylactic and MRD-triggered intervention with imatinib result in a low rate of hematologic relapse, durable remissions and excellent long-term outcome in patients with Ph þ ALL. Second-generation TKI may be beneficial in patients who remain MRD positive and do not benefit from posttransplant imatinib. The optimal duration of imatinib therapy and algorithms for its discontinuation remain to be established.
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